CARotid plaqUe StabilizatiOn and regression with evolocumab: the CARUSO Study
The CARUSO study, a randomized trial of patients with significant carotid stenosis, found that while adding evolocumab to standard lipid-lowering therapy did not statistically significantly improve plaque stabilization or regression compared to therapy alone, it was associated with a sevenfold reduction in major adverse vascular events and prevented morphological deterioration, suggesting evolocumab should be considered standard treatment for this population.